Isatuximab

• Isatuximab is a monoclonal antibody specifically designed to target the CD38 protein on multiple myeloma cells.
• It is primarily used in combination with other agents for the treatment of relapsed or refractory multiple myeloma.
• The isatuximab mechanism of action involves directly killing cancer cells and enhancing the immune system’s ability to fight them.
• Common isatuximab side effects include infusion-related reactions, infections, and low blood cell counts.
• Important isatuximab drug information emphasizes careful administration and monitoring for adverse events.

What is Isatuximab?

Isatuximab is a CD38-directed cytolytic monoclonal antibody. This means it is a type of immunotherapy that specifically targets the CD38 protein, which is highly expressed on the surface of multiple myeloma cells, a cancer of plasma cells. By binding to CD38, isatuximab initiates several mechanisms that lead to the death of cancer cells and helps to modulate the immune system to fight the disease.

Multiple myeloma is a relatively rare cancer, accounting for about 1.8% of all new cancer cases in the United States, with an estimated 35,730 new cases in 2024, according to the American Cancer Society. Isatuximab offers a crucial treatment option, particularly for patients whose disease has progressed despite prior therapies.

Isatuximab: Mechanism of Action and Clinical Uses

The isatuximab mechanism of action is multifaceted. Upon binding to CD38 on myeloma cells, it triggers direct cell death through several pathways, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Additionally, isatuximab can modulate the activity of certain immune cells, such as natural killer (NK) cells and T-cells, enhancing their ability to recognize and eliminate cancer cells. It also inhibits the enzymatic activity of CD38, which can play a role in immune suppression.

Isatuximab is primarily used for the treatment of adult patients with relapsed or refractory multiple myeloma. It is typically administered intravenously in combination with other anti-myeloma agents. For example, it is approved for use in combination with pomalidomide and dexamethasone for patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. It is also approved in combination with carfilzomib and dexamethasone for patients who have received one to three prior lines of therapy. These combinations aim to enhance the overall therapeutic effect and improve patient outcomes.

Isatuximab Side Effects and Important Drug Information

Like all medications, isatuximab side effects can occur. Patients should be closely monitored during and after infusions for potential adverse reactions. Common side effects include:

• Infusion-related reactions (e.g., chills, shortness of breath, cough, fever)
• Infections (e.g., upper respiratory tract infections, pneumonia)
• Low blood cell counts (e.g., neutropenia, thrombocytopenia, anemia)
• Diarrhea
• Fatigue

Serious side effects, though less common, can include severe infusion reactions, serious infections, and secondary primary malignancies. Patients are often pre-medicated with corticosteroids, antihistamines, and antipyretics to reduce the risk and severity of infusion-related reactions.

Important isatuximab drug information also includes considerations for administration and patient monitoring. Due to its mechanism of action, isatuximab can interfere with certain laboratory tests, such as serological testing for blood transfusions (indirect antiglobulin test), requiring specific blood typing procedures. Healthcare providers must be aware of these interferences to ensure accurate results and safe patient care. Patients receiving isatuximab should report any new or worsening symptoms to their healthcare team promptly.

It is crucial for patients to discuss all potential risks and benefits with their healthcare provider before starting treatment with Isatuximab. This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.